Sonja Gordic1,2, Jad Bou Ayache3, Paul Kennedy1, Cecilia Besa1, Mathilde Wagner1, Octavia Bane1, Richard L Ehman4, Edward Kim3, Bachir Taouli5,6. 1. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY, 10029-6574, USA. 2. Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland. 3. Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 4. Department of Radiology, Mayo Clinic, Rochester, MN, USA. 5. Translational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1234, New York, NY, 10029-6574, USA. bachir.taouli@mountsinai.org. 6. Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. bachir.taouli@mountsinai.org.
Abstract
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived. 52 patients (M/F 38/14, mean age 67 years) with HCC who underwent RE (n = 22) or TACE/RFA (n = 30) and 11 controls (M/F 6/5, mean age 64 years) with newly diagnosed untreated HCC were included. The MRI protocol included a 2D MRE sequence. TS and LS (liver stiffness) were measured on stiffness maps. Degree of tumor necrosis was assessed on subtraction images by two observers, and tumor enhancement ratios (ER) were calculated on CE-T1WI by one observer. RESULTS: 63 HCCs (mean size 3.2 ± 1.6 cm) were evaluated. TS was significantly lower in treated vs. untreated tumors (3.9 ± 1.8 vs. 6.9 ± 3.4 kPa, p = 0.006) and also compared to LS (5.3 ± 2.2 kPa, p = 0.002). There were significant correlations between TS and each of enhancement ratios (r = 0.514, p = 0.0001), and percentage of necrosis (r = -0.540, p = 0.0001). The observed correlations were stronger in patients treated with RE (TS vs. ER, r = 0.636, TS vs. necrosis, r = -0.711, both p = 0.0001). Percentage of necrosis and T1-signal in native T1WI were significant independent predictors of TS (p = 0.0001 and 0.001, respectively). CONCLUSION: TS measured with MRE shows a significant correlation with tumor enhancement and necrosis, especially in HCCs treated with RE.
PURPOSE: The aim of the study was to correlate tumor stiffness (TS) measured with MR elastography (MRE) with degree of tumor enhancement and necrosis on contrast-enhanced T1-weighted imaging (CE-T1WI) in hepatocellular carcinomas (HCC) treated with Yttrium-90 radioembolization (RE) or transarterial chemoembolization plus radiofrequency ablation (TACE/RFA). MATERIAL AND METHODS: This retrospective study was IRB-approved and the requirement for informed consent was waived. 52 patients (M/F 38/14, mean age 67 years) with HCC who underwent RE (n = 22) or TACE/RFA (n = 30) and 11 controls (M/F 6/5, mean age 64 years) with newly diagnosed untreated HCC were included. The MRI protocol included a 2D MRE sequence. TS and LS (liver stiffness) were measured on stiffness maps. Degree of tumor necrosis was assessed on subtraction images by two observers, and tumor enhancement ratios (ER) were calculated on CE-T1WI by one observer. RESULTS: 63 HCCs (mean size 3.2 ± 1.6 cm) were evaluated. TS was significantly lower in treated vs. untreated tumors (3.9 ± 1.8 vs. 6.9 ± 3.4 kPa, p = 0.006) and also compared to LS (5.3 ± 2.2 kPa, p = 0.002). There were significant correlations between TS and each of enhancement ratios (r = 0.514, p = 0.0001), and percentage of necrosis (r = -0.540, p = 0.0001). The observed correlations were stronger in patients treated with RE (TS vs. ER, r = 0.636, TS vs. necrosis, r = -0.711, both p = 0.0001). Percentage of necrosis and T1-signal in native T1WI were significant independent predictors of TS (p = 0.0001 and 0.001, respectively). CONCLUSION: TS measured with MRE shows a significant correlation with tumor enhancement and necrosis, especially in HCCs treated with RE.
Authors: Temel Kaya Yasar; Mathilde Wagner; Octavia Bane; Cecilia Besa; James S Babb; Stephan Kannengiesser; Maggie Fung; Richard L Ehman; Bachir Taouli Journal: J Magn Reson Imaging Date: 2015-10-15 Impact factor: 4.813
Authors: A Manduca; T E Oliphant; M A Dresner; J L Mahowald; S A Kruse; E Amromin; J P Felmlee; J F Greenleaf; R L Ehman Journal: Med Image Anal Date: 2001-12 Impact factor: 8.545
Authors: Sudhakar K Venkatesh; Meng Yin; James F Glockner; Naoki Takahashi; Philip A Araoz; Jayant A Talwalkar; Richard L Ehman Journal: AJR Am J Roentgenol Date: 2008-06 Impact factor: 3.959
Authors: Ahsun Riaz; Laura Kulik; Robert J Lewandowski; Robert K Ryu; Georgia Giakoumis Spear; Mary F Mulcahy; Michael Abecassis; Talia Baker; Vanessa Gates; Ritu Nayar; Frank H Miller; Kent T Sato; Reed A Omary; Riad Salem Journal: Hepatology Date: 2009-04 Impact factor: 17.425
Authors: Philippe Garteiser; Sabrina Doblas; Jean-Luc Daire; Mathilde Wagner; Helena Leitao; Valérie Vilgrain; Ralph Sinkus; Bernard E Van Beers Journal: Eur Radiol Date: 2012-05-10 Impact factor: 5.315
Authors: David A Hormuth; Anna G Sorace; John Virostko; Richard G Abramson; Zaver M Bhujwalla; Pedro Enriquez-Navas; Robert Gillies; John D Hazle; Ralph P Mason; C Chad Quarles; Jared A Weis; Jennifer G Whisenant; Junzhong Xu; Thomas E Yankeelov Journal: J Magn Reson Imaging Date: 2019-03-29 Impact factor: 4.813
Authors: Paul Kennedy; Mathilde Wagner; Laurent Castéra; Cheng William Hong; Curtis L Johnson; Claude B Sirlin; Bachir Taouli Journal: Radiology Date: 2018-03 Impact factor: 11.105
Authors: Robert M Pohlman; James L Hinshaw; Timothy J Ziemlewicz; Meghan G Lubner; Shane A Wells; Fred T Lee; Marci L Alexander; Kelly L Wergin; Tomy Varghese Journal: Ultrasound Med Biol Date: 2021-05-16 Impact factor: 3.694